Obicetrapib alone and in combination with ezetimibe increases reverse cholesterol transport and does not affect VLDL production
Atherosclerosis, vol. 407, pp. 119531
Authors 10
-
Netherlands Organisation for Applied Scientific Research · Leiden University Medical Center
Affiliation as printed
Cardiology, LUMC, Leiden, Netherlands
Einthoven Laboratory For Experimental Vascular Medicine, LUMC, Leiden, Netherlands
Metabolic Health Research, TNO, Leiden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
-
NewAmsterdam Pharma (Netherlands)
Affiliation as printed
NewAmsterdam Pharma, Naarden, Netherlands
-
Leiden University Medical Center · Netherlands Heart Institute
Affiliation as printed
Cardiology, LUMC, Leiden, Netherlands
Einthoven Laboratory For Experimental Vascular Medicine, LUMC, Leiden, Netherlands
Netherlands Heart Institute, Utrecht, Netherlands
-
Amsterdam University Medical Centers · NewAmsterdam Pharma (Netherlands)
Affiliation as printed
Amsterdam UMC, Amsterdam, Netherlands
NewAmsterdam Pharma, Naarden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
-
Netherlands Organisation for Applied Scientific Research
Affiliation as printed
Metabolic Health Research, TNO, Leiden, Netherlands
Cited by 0 stored of 0
No patents citing this paper on Lens.org (checked 2026-10-11).